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Optic disc edema or papillitis is commonly associated 
with chronic anterior uveitis in children, and its prevalence 
has been reported to be 21% [1]. However, there have been 
few reports regarding the treatment for recalcitrant uveitic 
disc edema, especially in children [2]. Methotrexate, a 
member of the antimetabolite class, has been used as an 
immunosuppressive agent that is effective against ocular 
inflammatory disease [3]. Here, we report two cases of 
children with chronic recurrent uveitis and disc edema 
that did not respond to oral corticosteroid but that showed 
significant improvement following administration of 
methotrexate.
Case Report
Case 1
A 13-year-old male patient presented with bilateral 
optic disc edema accompanied by idiopathic chronic 
anterior uveitis that had been ongoing for two months. 
At that time, his visual acuity was 20 / 25 in the right 
eye and 20 / 40 in the left eye, and there was no macula 
edema on funduscopic examination or optical coherence 
tomography. He had been taking 30 mg (0.52 mg/kg) of 
oral prednisolone daily. We could not find any neurologic 
or systemic abnormalities to explain the disc edema. For 
six months, he had taken oral prednisolone and could not 
taper it due to the recurrence of ocular inflammation. In 
addition, the disc edema had not subsided, even with a high 
dose of oral prednisolone (60 mg [1.05 mg/kg] per day). 
Thereafter, we added oral methotrexate 10 mg (0.18 mg/
kg) per week to the daily dose of prednisolone 30 mg (0.52 
mg/kg). After 3 weeks of methotrexate, the disc edema 
and ocular inflammation were alleviated, and his vision 
improved to 20 / 20 in both eyes (Fig. 1A and 1B). The 
disc edema and inflammation recurred during the oral 
prednisolone tapering period. However, a daily low-to-
moderate dose of prednisolone (10-20 mg) combined with a 
weekly dose of methotrexate 15 mg (0.26 mg/kg) alleviated 
the ocular inflammation and disc edema (Fig. 1C and 1D). 
After 18 months of methotrexate and tapering the dose of 
oral prednisolone, the patient achieved stable vision without 
optic disc edema or ocular inflammation.
Case 2 
A 15-year-old female patient presented with optic disc 
A 13-year-old male and a 15-year-old female presented with optic disc edema associated with chronic recurrent 
uveitis. While the ocular inflammation responded to high doses of oral prednisolone, the disc edema showed 
little improvement. After oral administration of methotrexate, the disc edema and ocular inflammation were re-
solved, and the dose of oral corticosteroid could be reduced. 
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Fig. 1. Case 1. Fundus photographs of case 1. (A,B) At presentation, bilateral severe disc edema and vascular tortuosity were observed. (C,D) 
Three weeks after administration of methotrexate, disc edema and vascular tortuosity were resolved.
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edema in the right eye and bilateral idiopathic panuveitis 
(Fig. 2A and 2B) with no associated neurologic or systemic 
abnormalities. Despite continued daily administration 
of oral prednisolone 30 mg (0.44 mg/kg) for 4 months, 
the disc edema persisted. We added a daily dose of 
cyclosporine 150 mg (2.21 mg/kg) to her medications. 
Although the anterior chamber inflammation had improved 
significantly, the disc edema persisted. We then prescribed 
a weekly dose of methotrexate, starting at 7.5 mg (0.11 mg/
kg) and increasing to 15 mg (0.22 mg/kg), while reducing 
the prednisolone dose to 10 mg (0.15 mg/kg) per day and 
discontinuing the cyclosporine. The disc edema resolved 
dramatically one month after the initiation of methotrexate 
(Fig. 2C and 2D). The dose of oral prednisolone was 
tapered while increasing the dose of methotrexate to 20 
mg weekly without recurrence of disc edema or ocular 
inflammation. After one year of methotrexate, the patient 
had good visual acuity in both eyes, and the intraocular 
inflammation was controlled without optic disc edema.
Discussion
Optic disc edema from various causes may result in 
irreversible axonal damage and progressive visual field loss 
[4]. Although there have been reports of resolution of optic 
disc edema after successful treatment of anterior uveitis 
[2,5], there is no definite treatment guideline for uveitic disc 
edema in children who do not respond to corticosteroids. 
While corticosteroids are one of the traditional treatment 
regimens of uveitis, chronic oral intake by children can 63
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Fig. 2. Case 2. A fundus photograph (A) and fluorescein angiography (B) of the right eye revealing disc edema and choroiditis. (C,D). One 
month after administration of methotrexate, the disc edema and fluorescein leakage from the optic disc were resolved. 
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lead to serious side effects, i.e., cataract, glaucoma, and 
growth retardation in prepubescent children. Recent studies 
have reported that methotrexate is moderately effective 
for controlling ocular inflammation and for achieving 
corticosteroid-sparing objectives as a monotherapy or in 
combination with other agents in both adults and children 
[3,6,7]. 
For long-term treatment with methotrexate, caution 
should be exercised regarding the systemic and ocular side 
effects. Elevated liver enzymes, nausea, fatigue, cytopenia, 
stomatitis, bone marrow suppression and liver cirrhosis 
have been reported as systemic side effects of methotrexate 
[8-12]. Ocular side effects include irritation and dry eye [13], 
as well as the rare occurrence of toxic optic neuropathy, 
which can be reversed by the intake of folic acid [14-17]. 
Thus, regular ophthalmic and systemic examination is 
mandatory during methotrexate intake. 
In our cases of steroid-refractory uveitic optic disc 
edema in children, methotrexate had a beneficial effect 
on the resolution of optic disc edema and controlled 
intraocular inflammation while sparing the corticosteroid. 
We are unaware of previous reports showing the efficacy 
of methotrexate reducing recalcitrant uveitic disc edema in 
children. Therefore, we think that this report is a significant 
reference regarding the effect of methotrexate in the 
treatment of pediatric uveitis accompanying disc edema. 64
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